Ns Pharma, Inc.
Clinical trials sponsored by Ns Pharma, Inc., explained in plain language.
-
New hope for rare disease: can NS-229 help patients cut steroids?
Disease control Recruiting nowThis study tests a new drug, NS-229, for people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission (no symptoms) while taking a lower dose of…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New drug aims to restore muscle protein in boys with DMD
Disease control Recruiting nowThis study tests a weekly intravenous drug, NS-089/NCNP-02, in 20 boys aged 4 to 14 with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The goal is to help their bodies produce a missing muscle protein, dystrophin, to slow muscle damage. Participants must…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated May 13, 2026 16:04 UTC